Acorda Presenting New Tozadenant Data at 2017 MDS Congress

06:00 EDT 6 Jun 2017 | Businesswire
This article has expired, however you can still download the PDF.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) is presenting new data from clinical and preclinical studies of tozadenant at the 2017 International Congress of Parkinson’s Disease and Movement Disorders (MDS), being held in Vancouve...

Other Sources for this Article

Acorda Therapeutics, Inc.
Felicia Vonella, 914-326-5146


More From BioPortfolio on "Acorda Presenting New Tozadenant Data at 2017 MDS Congress"

Quick Search

Relevant Topic

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...